Clinical TrialMay 14, 2026, 07:07 AM
Corvus Soquelitinib Phase 1 AD Trial Shows Durable Remissions
AI Summary
Corvus Pharmaceuticals presented positive final Phase 1 clinical trial data for soquelitinib in moderate-to-severe atopic dermatitis, demonstrating safety and efficacy, including in treatment-resistant patients. The trial showed durable remissions with no disease rebound post-treatment, a key differentiator from existing therapies. Biomarker data supported the drug's novel mechanism of action, suggesting potential for drug-free remissions and rebalancing the immune system. The company is now enrolling patients for a Phase 2 trial.
Key Highlights
- Soquelitinib Phase 1 trial showed positive safety and efficacy in moderate-to-severe atopic dermatitis.
- Cohort 4 (56-day treatment) achieved 75% EASI 75, 25% EASI 90, and 33% IGA 0/1.
- Cohort 3 (28-day treatment) achieved 50% EASI 75, 8% EASI 90, and 25% IGA 0/1.
- Disease control was durable post-treatment, with no rebound or rescue medication needed.
- No significant safety issues; adverse events were Grade 1-2, with no serious events reported.
- Biomarker data supports ITK inhibition, blocking Th2/Th17, and increasing Treg cells.
- Corvus is enrolling a Phase 2 trial for soquelitinib in atopic dermatitis (approx. 200 patients).
- Angel Pharmaceuticals (China partner) is also enrolling a Phase 1b/2 trial for soquelitinib.
- sentiment